Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
AssigneeCellectis
InventorsPhilippe Duchateau, Laurent Poirot
Life of this patent
Estimating the term…
Abstract
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Claims18
A method of preparing an immune cell for immunotherapy comprising:
- (a) inactivating or mutating a gene encoding a CD38 antigen marker in an immune cell;
- and
- (b) expressing in said immune cell a transgene encoding a chimeric antigen receptor (CAR) directed against said CD38 antigen marker.
A method of preparing an immune cell for immunotherapy comprising inactivating or mutating a gene encoding a CD38 antigen marker in an immune cell using a rare-cutting endonuclease.
An engineered immune cell comprising,
- an inactivated or mutated gene encoding a CD38 antigen marker, wherein said CD38 antigen marker is inactivated or mutated by cleavage with a rare-cutting endonuclease and
- a transgene encoding a chimeric antigen receptor (CAR).
Dependencies are inferred from the claim text.